Understanding cancer incidence in barrett's esophagus: Light at the end of the tunnel

Journal of the National Cancer Institute

Volumn 103, Issue 13, 2011, Pages 994-995

  Corley, Douglas A ^a  

^a DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; EDITORIAL; ESOPHAGEAL ADENOCARCINOMA; HUMAN; INTESTINE METAPLASIA; PRIORITY JOURNAL; SEX DIFFERENCE;

ADENOCARCINOMA; AGE FACTORS; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; HUMANS; INCIDENCE; INTESTINES; METAPLASIA; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 79960257741     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr223     Document Type: Editorial

References (10)

1. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049-1057.
2. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94(8):2043-2053. (Pubitemid 29374530)
3. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138(3):176-186. (Pubitemid 36231623)
4. Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther. 2007;26(11-12):1465-1477. (Pubitemid 350178802)
5. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(3):237-249. (Pubitemid 352019777)
6. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011;140(3):1084-1091.
7. American Heart Association. Heart Attack Risk Calculator. http://www.americanheart.org/gglRisk/locale/en-US/index.html?gtype=health. Accessed November 15, 2010.
8. Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds DA. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst. 2010;102(21):1618-1627.
9. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4(2):e67.
10. Sikkema M, Kerkhof M, Steyerberg EW, et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol. 2009;104(11):2673-2680.